UB Paderborn / Katalog / Suche / in CDI

Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

CPT: pharmacometrics and systems pharmacology, 2013-06, Vol.2 (6), p.1-9

2013

Link zum Volltext

Verfügbarkeit prüfen

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Clinical pharmacology and therapeutics, 2017-03, Vol.101 (3), p.341-358

2017

Link zum Volltext

Verfügbarkeit prüfen

Xpose : an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

Computer methods and programs in biomedicine, 1999, Vol.58 (1), p.51-64

1999

Link zum Volltext

Verfügbarkeit prüfen

Automated covariate model building within NONMEM

Pharmaceutical research, 1998-09, Vol.15 (9), p.1463-1468

1998

Link zum Volltext

Verfügbarkeit prüfen

A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first‐pass hepatic extraction

British journal of clinical pharmacology, 2005-02, Vol.59 (2), p.189-198

2005

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin

Clinical pharmacology and therapeutics, 2008-07, Vol.84 (1), p.52-62

2008

Link zum Volltext

Verfügbarkeit prüfen

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

CPT: pharmacometrics and systems pharmacology, 2017-02, Vol.6 (2), p.87-109

2017

Link zum Volltext

Verfügbarkeit prüfen

Drug and Disease Model Resources: A Consortium to Create Standards and Tools to Enhance Model‐Based Drug Development

CPT: pharmacometrics and systems pharmacology, 2013-03, Vol.2 (3), p.1-3

2013

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic Modeling of a Magnetic Marker Monitoring Study Linking Gastrointestinal Tablet Transit, In Vivo Drug Release, and Pharmacokinetics

Clinical pharmacology and therapeutics, 2009-07, Vol.86 (1), p.77-83

2009

Link zum Volltext

Verfügbarkeit prüfen

The importance of modeling interoccasion variability in population pharmacokinetic analyses

Journal of pharmacokinetics and biopharmaceutics, 1993-12, Vol.21 (6), p.735-750

1993

Link zum Volltext

Verfügbarkeit prüfen

A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6

PloS one, 2019-02, Vol.14 (2), p.e0211981-e0211981

2019

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

Bone marrow transplantation (Basingstoke), 2001-10, Vol.28 (7), p.657-664

2001

Link zum Volltext

Verfügbarkeit prüfen

Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials

Journal of clinical pharmacology, 2018-10, Vol.58 (10), p.1284-1294

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic/Pharmacodynamic Modelling in Oncological Drug Development

Basic & clinical pharmacology & toxicology, 2005-03, Vol.96 (3), p.206-211

2005

Link zum Volltext

Verfügbarkeit prüfen

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

CPT: pharmacometrics and systems pharmacology, 2013-06, Vol.2 (6), p.1-2

2013

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug‐Resistant Tuberculosis: The Effect of Time‐Varying Weight and Albumin

CPT: pharmacometrics and systems pharmacology, 2016-12, Vol.5 (12), p.682-691

2016

Link zum Volltext

Verfügbarkeit prüfen

Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

Journal of clinical oncology, 2002-12, Vol.20 (24), p.4713-4721

2002

Link zum Volltext

Verfügbarkeit prüfen

Model averaging for robust assessment of QT prolongation by concentration‐response analysis

Statistics in medicine, 2017-10, Vol.36 (24), p.3844-3857

2017

Link zum Volltext

Verfügbarkeit prüfen

A model-based longitudinal meta-analysis of FEV1 in randomized COPD trials

Clinical pharmacology and therapeutics, 2016-03, Vol.99 (3), p.315-324

2016

Link zum Volltext

Verfügbarkeit prüfen

A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 — Estimating occupancy in the absence of a reference region

NeuroImage (Orlando, Fla.), 2013-11, Vol.82, p.160-169

2013

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments

CPT: pharmacometrics and systems pharmacology, 2013-10, Vol.2 (10), p.1-8

2013

Link zum Volltext

Verfügbarkeit prüfen

Modelling a spontaneously reported side effect by use of a markov mixed-effects model

Journal of pharmacokinetics and pharmacodynamics, 2005-04, Vol.32 (2), p.261-281

2005

Link zum Volltext

Verfügbarkeit prüfen

Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia

Clinical pharmacology and therapeutics, 2009-07, Vol.86 (1), p.84-91

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Xpose : an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

Automated covariate model building within NONMEM

A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first‐pass hepatic extraction

Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

Drug and Disease Model Resources: A Consortium to Create Standards and Tools to Enhance Model‐Based Drug Development

Mechanistic Modeling of a Magnetic Marker Monitoring Study Linking Gastrointestinal Tablet Transit, In Vivo Drug Release, and Pharmacokinetics

The importance of modeling interoccasion variability in population pharmacokinetic analyses

A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6

Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials

Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

Pharmacokinetic/Pharmacodynamic Modelling in Oncological Drug Development

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug‐Resistant Tuberculosis: The Effect of Time‐Varying Weight and Albumin

Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

Model averaging for robust assessment of QT prolongation by concentration‐response analysis

A model-based longitudinal meta-analysis of FEV1 in randomized COPD trials

A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 — Estimating occupancy in the absence of a reference region

Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments

Modelling a spontaneously reported side effect by use of a markov mixed-effects model

Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia

Suchergebnisse filtern